Matches in SemOpenAlex for { <https://semopenalex.org/work/W1844205524> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W1844205524 endingPage "19511" @default.
- W1844205524 startingPage "19511" @default.
- W1844205524 abstract "19511 Background: Application of peg-f is recommended on day 2 of chemotherapy, but later application has not been studied. Objective: To compare the effects of peg-f given on day 4 instead of day 2 on the endpoints feasibility, leukocyte counts, rate of infections and therapy-associated deaths after CHOP-14 with and without rituximab (R). Methods: Intention-to-treat-analysis of 109 elderly patients (median 69 years) with DLBCL receiving CHOP-14 or R-CHOP-14 randomized to peg-f on day 2 or day 4 (D4). Results: Of 103 evaluable pats., 51 received peg-f on day 2 (D2) and 52 on day 4 (D4). D2 and D4 populations were well balanced for known risk factors, and there was no difference between pats. receiving CHOP-14 and R-CHOP-14 with respect to the above mentioned endpoints. Both D2 and D4 allowed for an excellent adherence to (R)-CHOP-14 protocol, with a median relative dose of myelosuppressive drugs of 98% (D2) and 99% (D4), respectively. Leukocytopenia <2,000/mm 3 lasted for 3 (day 8 to 10) after D2 and 1 day (day 9) after D4. Grade 4 leukocytopenia (<1,000/mm 3 ) occurred in 47% of all cycles after D2 and in 20.5% after D4 (p<0.001). Grade 3 and 4 infections occurred in 9.4% of D2 and 6.0% of D4 cycles (p=0.118). There were 4 therapy-associated deaths (all infection-associated) in the D2 and 1 (none infection-associated) in the D4 group (p=0.205 for all and p=0.057 for infection-associated deaths). Conclusions: Peg-f allows for excellent adherence of elderly patients to (R)-CHOP-14. Peg-f should be given on day 4 instead of day 2, because D4 results in less leukocytopenia, less infections and less therapy-associated deaths. No significant financial relationships to disclose." @default.
- W1844205524 created "2016-06-24" @default.
- W1844205524 creator A5011827144 @default.
- W1844205524 creator A5014121057 @default.
- W1844205524 creator A5023251571 @default.
- W1844205524 creator A5025964385 @default.
- W1844205524 creator A5030332519 @default.
- W1844205524 creator A5057055234 @default.
- W1844205524 creator A5060744519 @default.
- W1844205524 creator A5073040549 @default.
- W1844205524 creator A5083692322 @default.
- W1844205524 creator A5090758804 @default.
- W1844205524 date "2007-06-20" @default.
- W1844205524 modified "2023-10-14" @default.
- W1844205524 title "Peg-filgrastim (Peg-F) on day 4 of (R-)CHOP-14 chemotherapy compared to day 2 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of a randomized trial of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL)" @default.
- W1844205524 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.19511" @default.
- W1844205524 hasPublicationYear "2007" @default.
- W1844205524 type Work @default.
- W1844205524 sameAs 1844205524 @default.
- W1844205524 citedByCount "8" @default.
- W1844205524 countsByYear W18442055242020 @default.
- W1844205524 crossrefType "journal-article" @default.
- W1844205524 hasAuthorship W1844205524A5011827144 @default.
- W1844205524 hasAuthorship W1844205524A5014121057 @default.
- W1844205524 hasAuthorship W1844205524A5023251571 @default.
- W1844205524 hasAuthorship W1844205524A5025964385 @default.
- W1844205524 hasAuthorship W1844205524A5030332519 @default.
- W1844205524 hasAuthorship W1844205524A5057055234 @default.
- W1844205524 hasAuthorship W1844205524A5060744519 @default.
- W1844205524 hasAuthorship W1844205524A5073040549 @default.
- W1844205524 hasAuthorship W1844205524A5083692322 @default.
- W1844205524 hasAuthorship W1844205524A5090758804 @default.
- W1844205524 hasConcept C126322002 @default.
- W1844205524 hasConcept C141071460 @default.
- W1844205524 hasConcept C2776694085 @default.
- W1844205524 hasConcept C2777063308 @default.
- W1844205524 hasConcept C2778658803 @default.
- W1844205524 hasConcept C2779171977 @default.
- W1844205524 hasConcept C2779338263 @default.
- W1844205524 hasConcept C2779725641 @default.
- W1844205524 hasConcept C2780653079 @default.
- W1844205524 hasConcept C2909463153 @default.
- W1844205524 hasConcept C71924100 @default.
- W1844205524 hasConcept C90924648 @default.
- W1844205524 hasConceptScore W1844205524C126322002 @default.
- W1844205524 hasConceptScore W1844205524C141071460 @default.
- W1844205524 hasConceptScore W1844205524C2776694085 @default.
- W1844205524 hasConceptScore W1844205524C2777063308 @default.
- W1844205524 hasConceptScore W1844205524C2778658803 @default.
- W1844205524 hasConceptScore W1844205524C2779171977 @default.
- W1844205524 hasConceptScore W1844205524C2779338263 @default.
- W1844205524 hasConceptScore W1844205524C2779725641 @default.
- W1844205524 hasConceptScore W1844205524C2780653079 @default.
- W1844205524 hasConceptScore W1844205524C2909463153 @default.
- W1844205524 hasConceptScore W1844205524C71924100 @default.
- W1844205524 hasConceptScore W1844205524C90924648 @default.
- W1844205524 hasIssue "18_suppl" @default.
- W1844205524 hasLocation W18442055241 @default.
- W1844205524 hasOpenAccess W1844205524 @default.
- W1844205524 hasPrimaryLocation W18442055241 @default.
- W1844205524 hasRelatedWork W180056525 @default.
- W1844205524 hasRelatedWork W1983333001 @default.
- W1844205524 hasRelatedWork W2053128632 @default.
- W1844205524 hasRelatedWork W2374533761 @default.
- W1844205524 hasRelatedWork W2442769633 @default.
- W1844205524 hasRelatedWork W2564813588 @default.
- W1844205524 hasRelatedWork W2590806005 @default.
- W1844205524 hasRelatedWork W2958331463 @default.
- W1844205524 hasRelatedWork W2969121529 @default.
- W1844205524 hasRelatedWork W3082112758 @default.
- W1844205524 hasVolume "25" @default.
- W1844205524 isParatext "false" @default.
- W1844205524 isRetracted "false" @default.
- W1844205524 magId "1844205524" @default.
- W1844205524 workType "article" @default.